Literature DB >> 22537616

The development of a decision analytic model of changes in mean deviation in people with glaucoma: the COA model.

Steven M Kymes1, Dennis L Lambert, Paul P Lee, David C Musch, Carla J Siegfried, Sameer V Kotak, Dustin L Stwalley, Joel Fain, Chris Johnson, Mae O Gordon.   

Abstract

PURPOSE: To create and validate a statistical model predicting progression of primary open-angle glaucoma (POAG) assessed by loss of visual field as measured in mean deviation (MD) using 3 landmark studies of glaucoma progression and treatment.
DESIGN: A Markov decision analytic model using patient level data described longitudinal MD changes over 7 years. PARTICIPANTS: Patient-level data from the Collaborative Initial Glaucoma Treatment Study (n = 607), the Ocular Hypertension Treatment Study (OHTS; n = 148; only those who developed POAG in the first 5 years of OHTS) and Advanced Glaucoma Intervention Study (n = 591), the COA model.
METHODS: We developed a Markov model with transition matrices stratified by current MD, age, race, and intraocular pressure categories and used a microsimulation approach to estimate change in MD over 7 years. Internal validation compared model prediction for 7 years to actual MD for COA participants. External validation used a cohort of glaucoma patients drawn from university clinical practices. MAIN OUTCOME MEASURES: Change in visual field as measured in MD in decibels (dB).
RESULTS: Regressing the actual MD against the predicted produced an R(2) of 0.68 for the right eye and 0.63 for the left. The model predicted ending MD for right eyes of 65% of participants and for 63% of left eyes within 3 dB of actual results at 7 years. In external validation the model had an R(2) of 0.79 in the right eye and 0.77 in the left at 5 years.
CONCLUSIONS: The COA model is a validated tool for clinicians, patients, and health policy makers seeking to understand longitudinal changes in MD in people with glaucoma.
Copyright © 2012 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22537616      PMCID: PMC3389134          DOI: 10.1016/j.ophtha.2012.01.054

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  19 in total

Review 1.  The role of modelling in prioritising and planning clinical trials.

Authors:  J Chilcott; A Brennan; A Booth; J Karnon; P Tappenden
Journal:  Health Technol Assess       Date:  2003       Impact factor: 4.014

2.  Primer on medical decision analysis: Part 5--Working with Markov processes.

Authors:  D Naimark; M D Krahn; G Naglie; D A Redelmeier; A S Detsky
Journal:  Med Decis Making       Date:  1997 Apr-Jun       Impact factor: 2.583

3.  Management of ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study.

Authors:  Steven M Kymes; Michael A Kass; Douglas R Anderson; J Philip Miller; Mae O Gordon
Journal:  Am J Ophthalmol       Date:  2006-06       Impact factor: 5.258

Review 4.  Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study.

Authors:  P Mitchell; W Smith; K Attebo; J J Wang
Journal:  Ophthalmology       Date:  1995-10       Impact factor: 12.079

5.  The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.

Authors:  Michael A Kass; Dale K Heuer; Eve J Higginbotham; Chris A Johnson; John L Keltner; J Philip Miller; Richard K Parrish; M Roy Wilson; Mae O Gordon
Journal:  Arch Ophthalmol       Date:  2002-06

6.  The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study.

Authors:  R Klein; B E Klein; S C Jensen; S M Meuer
Journal:  Ophthalmology       Date:  1997-01       Impact factor: 12.079

7.  Prediction models for insulin resistance in girls with premature adrenarche. The premature adrenarche insulin resistance score: PAIR score.

Authors:  Patricia Vuguin; Gabriela Grinstein; Katherine Freeman; Paul Saenger; Joan DiMartino Nardi
Journal:  Horm Res       Date:  2006-03-17

8.  Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye Study.

Authors:  Rohit Varma; Mei Ying-Lai; Brian A Francis; Betsy Bao-Thu Nguyen; Jennifer Deneen; M Roy Wilson; Stanley P Azen
Journal:  Ophthalmology       Date:  2004-08       Impact factor: 12.079

9.  Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.

Authors:  Anders Heijl; M Cristina Leske; Bo Bengtsson; Leslie Hyman; Boel Bengtsson; Mohamed Hussein
Journal:  Arch Ophthalmol       Date:  2002-10

10.  Evaluating several sources of variability for standard and SWAP visual fields in glaucoma patients, suspects, and normals.

Authors:  Eytan Z Blumenthal; Pamela A Sample; Charles C Berry; Alexander C Lee; Christopher A Girkin; Linda Zangwill; Joseph Caprioli; Robert N Weinreb
Journal:  Ophthalmology       Date:  2003-10       Impact factor: 12.079

View more
  2 in total

1.  Development and validation of an improved neurological hemifield test to identify chiasmal and postchiasmal lesions by automated perimetry.

Authors:  Allison N McCoy; Harry A Quigley; Jiangxia Wang; Neil R Miller; Prem S Subramanian; Pradeep Y Ramulu; Michael V Boland
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-02-20       Impact factor: 4.799

2.  Effect of quantitative intraocular pressure reduction on visual field defect progression in normal tension glaucoma under medical therapy applying Markov model.

Authors:  Keiji Yoshikawa; Kazunori Santo; Hiroko Hizaki; Masayo Hashimoto
Journal:  Clin Ophthalmol       Date:  2018-08-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.